Tuesday 9th August 2022

Cambridge Cluster deal-flow shows no sign of slowing | Business Weekly | Technology News |

[ad_1]

Cambridge Cluster deals in the last 12 calendar months have held steady following a record year in 2019-20.

Last year we reported deals totalling $66.85 billion. Charting a period from early November 2020 to the end of October 2021, the haul this time around had topped $56.26bn – but that excludes a bid by NVIDIA for Arm. Approvals for the transaction from the UK, EU, China and US are awaited so this is far from a done deal.

Biotechnology transactions account for the majority of the $56.26bn deals total in the last year – $50bn involving M & A and the rest topped up by IPO and general funding. General technology deals accounted for around $3bn of the remainder, with IPOs in the segment totalling $2.29bn.

Financial advisers and law firms in the region tell Business Weekly they have record deals pipelines with deep-pocketed US and Asian investors primed to swoop for targets based in the region.

November 2020
The last year’s Deals figures are not as obviously transparent as we would like as many firms ducked behind ‘undisclosed’ agreements. No official figure could be nailed to F-star’s NASDAQ bow in November, for example. November 2020 was nevertheless momentous for life science transactions involving local firms.

Horizon Discovery was sold to PerkinElmer for $383 million; well-heeled Achilles Therapeutics raised more than $71m and Congenica a $50m Series C. And these were only the headline deals. Good money in smaller tranches was commonplace as startups scaled up and established players topped up.

December 2020
Cambridge Quantum stole the December headlines as it completed a $45m financing while there were healthy hauls for Endomag, Adrestia Therapeutics, IQGeo, Arkessa, Sunlight and 8power.Image courtesy of Kymab

January 2021
Just as deals are often rushed through to beat the Christmas break so transactions can be slow as January rolls around. Not this time! Therapeutic antibody company Kymab (pictured above) was acquired by Sanofi for a reported $1.45bn, while games developer Jagex was sold for the second time in eight months for an estimated $1/2bn.

The New Year continued to be lucrative for the region as Total Capital Partners invested $22.88m in PCML, Riverlane clinched a $20m Series A, Wren Therapeutics added $127m to its war chest, and Xampla, Turbine.ai and Sano Genetics posted significant raises.

February 2021
What a month this turned out to be for financial transactions in terms of variety and volume! The headline deal was the $7.2bn swoop by Irish company Jazz for fellow NASDAQ business GW Pharma. PayPoint completed a $94.21m acquisition of Handepay Limited and Merchant Rentals.

Inivata, a market leader in liquid biopsy technology, took its Series C round to $60m with a fresh $35m raise. There were significant fundraising rounds for Acacia Pharma, Nyobolt, Avacta, Optibrium and Charco; 4basebio floated on AIM in the UK.

March 2021
In the lively world of real estate, Connells completed the $174.96m takeover of Countrywide. Syncona cornerstoned a $148m Series C in eye disease tech specialist Gyroscope Tx. Out of left field, Cambridge biotech Eliem stormed out of stealth $80m richer with a vision to accelerate clinical programs addressing large markets with substantial unmet needs.

Chronic pain, depression, epilepsy and anxiety are some of the areas Eliem Therapeutics plans to address with its huge war chest and a five-star team of executives.

Cambridge biopharma business PhoreMost raised $46 million in an oversubscribed Series B round to accelerate key treatments into the clinic.The round was led by BGF, the UK’s most active growth economy investor, and included new investors XtalPi Inc. – anchored in Beijing and Boston US – Astellas Venture Management in California, Trend Investment Group, and Cambridge’s o2h ventures. Existing investors Parkwalk Advisors, Morningside Ventures and serial life sciences entrepreneur Jonathan Milner also contributed.

The funding will be used to progress PhoreMost’s preclinical ‘Allosteric PLK1’ collaboration with Sentinel Oncology into the clinic in 2022. The programme is initially targeted towards Glioma (brain tumours). NeoPhore meanwhile raided $20.48m Series B cash. There were important rounds for FocalPoint Positioning, Dunad Therapeutics, Monavate, FetchAI, Arecor and many others.Courtesy of Darktrace

April 2021
No doubt about the headline grabber here. Cyber security world leader Darktrace (above) lowered its UK IPO target expectations in the wake of a disastrous public bow by Deliveroo. It need not have worried. Darktrace was valued at $2.29bn on float, and at one stage recently, was close to a $10bn market cap. The long-awaited US IPO for Achilles Therapeutics realised $175.5m.

Cambridge then produced another blockbusting transaction as US investors backed a phenomenal $82m Series A for young startup Alchemab, which is advancing a unique target-agnostic drug discovery platform.

Cambridge startup Mestag, which is fighting inflammatory disease and cancer, launched with $11 million seed cash from healthcare backers SV Health Investors and Johnson & Johnson Innovation.

May 2021
It was revealed that AI technology from Cambridge could be set to revolutionise global health and beauty markets through an acquisition by a NASDAQ-quoted Californian company. Amyris Inc, a leading synthetic biotech business acquired BeautyLabs for an undisclosed fee. BeautyLabs was founded and steered by Mark Gerhard, the entrepreneur behind video games companies Jagex and PlayFusion. 

Eliem Therapeutics, which had made such a sensational bow, stole more headlines after raising $60m Series B financing – taking its haul to date to $140m.

World-leading cell therapy pioneer Mogrify took its Series A round to $33 million with a $17m second closing. The company is transforming the development of ex vivo cell therapies and steering a new class of in vivo reprogramming therapies. This second close of the company’s Series A was led by Parkwalk Advisors and incorporated additional funding from strategic corporate pharma investor Astellas Venture Management, as well as 24Haymarket, co-founder of Abcam Dr Jonathan Milner and Mogrify CEO, Dr Darrin Disley.

Marshall Motor Group acquired Cheltenham and Gloucester Jaguar Land Rover from Heritage Automotive for an undisclosed sum. Phico raised a fresh $9.43m to scale its fight against superbugs. Amino Technologies plc acquired Nordija, a Danish streaming and Pay TV platform specialist, for $6.5m.

NASDAQ powerhouse NeoGenomics Inc exercised its right to hoover up the whole of Cambridge liquid biopsy specialist Inivata. Having made a $25m minority investment in the Cambridge UK business, Florida-based 

NeoGenomics took up a fixed price option to buy the remainder for a further $390m. NeoGenomics is a leading provider of cancer-focused genetic testing services and global oncology contract research services. Inivata is a Cambridge Innovation Capital investee company.Courtesy of CMR Surgical

June 2021
What a deal this was to spark a sizzling summer of activity! CMR Surgical (above), the Cambridge-based global surgical robotics business, smashed all MedTech fundraising efforts with a new round that took its cash haul in recent years to just shy of $1billion. The round gave the business a valuation of more than $3bn. Arm’s parent SoftBank in Japan co-led the $600m Series D through its Vision Fund 2ii. The round was co-led by China’s Ally Bridge Group and will support the company’s mission to make keyhole surgery accessible to more people worldwide.

The heat was maintained as Cambridge Quantum announced it was combining with Honeywell Quantum Solutions, establishing the world’s most advanced, fully integrated quantum computing company. Honeywell will also invest between $270 million and $300m in the new venture.

Portfolio-based biopharma venture Apollo Therapeutics expanded its Cambridge UK and Boston US operations after raising $145m growth capital. Cambridge CleanTech business Origami raised £20.5m new funding to help drive its next phase of growth. Barclays PLC led the round, investing as part of its Sustainable Impact Capital initiative.

Arecor made an excellent bow on London’s AIM market with its market cap soaring to $98.9m at one point during its first day of trading. Arecor’s chairman Dr Andy Richards said: “Arecor has the potential to become a significant UK biopharmaceutical company and deliver benefits to patients and clinicians.”

Canadia’s OMERS Ventures led a $19m funding round in Agile Analog, a…

[ad_2]

Read More:Cambridge Cluster deal-flow shows no sign of slowing | Business Weekly | Technology News |